View all veterinary jobs
The online invitation survey was conducted among 6,500 pet owners from around the world, 1,000 of whom were based in the UK.
Whilst the survey didn't glean any further information about the nature of the infections, such as what percent of them were endoparasites versus ectoparasites, it did reveal that 61% of respondents said their pet experienced discomfort or illness, 39% said they showed behavioural changes and 38% reported that it made them feel anxious.
However, 38% see a parasite infection as not serious or just slightly serious.
Seventy per cent of owners said they get their parasite information from vets, compared to 43% from the internet.
Forty-five per cent use prescription treatments and 40% use vet-administered treatments in a clinic.
According to the company, 71% of UK pet owners said they would like clearer guidance on parasite protection, yet 35% have not been informed about parasite risks in their area by their vet.
Ian Wright MRCVS, Chairman/Director of ESCCAP (European Scientific Counsel Companion Animal Parasites), said: "It has never been more important to be aware of parasites and the risk to companion animals – the increased movement of pets and people, as well as climate change, has fuelled a rapid shift in the distribution of parasites and their proximity to pets.
"Pets can carry parasites which affect animal and human health - although there are familiar types, such as fleas – we need to be vigilant for unexpected parasites moving into new countries and regions.
"With simple precautions and preventative measures, we can minimise the risk of diseases they may bring, and continue to enjoy the wonderful benefits of pet ownership."
This allows patients to try the drug at lower cost, before progressing to the 30ml bottle for ongoing treatment.
Samantha Taylor, RCVS Recognised Specialist in Feline Medicine said: “It’s great we now have the option to prescribe the smaller 12ML bottle for starting cats on Senvelgo, as it means we don’t have to worry about wasting a 30ml bottle if it becomes evident that the cat requires insulin in the first couple of weeks.”
https://senvelgo.co.uk
The company says the two main benefits of the liquid formulation are precise dosing and ease of administration.
Vetmedin oral solution comes with a kg-bodyweight calibrated syringe to make it easy to give the preferred dose of 0.25 mg/kg twice daily to the nearest 0.5 kg bodyweight.
The maximum syringe volume is for a 12 kg dog.
The solution has a sweet taste to make it palatable and Boehringer says it is also ideal for dogs that need dental work but require treatment for their heart disease before general anaesthesia.
These dogs might struggle to eat chewable tablets due to oral discomfort, so a liquid treatment might be a better option.
The company highlights the EPIC1 and PROTECT2 studies which showed that Vetmedin delays the onset of CHF for dogs in the asymptomatic stage of heart disease and improves both the quality and length of life for dogs with MVD and DCM.
Vetmedin oral solution comes as a 50 ml bottle (each bottle lasts a 5 kg dog approximately 30 days), doesn't need to be refrigerated, has an 8-week shelf life once opened, and a 2-year shelf life as packaged.
VetMedin oral solution is now available to order from wholesalers.
References
The new product is being sold through e-retailers including Pet Drugs Online, Animed and Pets at Home.
Frontpro is claimed to kill fleas within 8 hours and protect dogs from fleas and ticks for one month.
It is suitable for all breeds aged eight weeks or older (weighing two kilograms or more) and can be given with or without food.
A company spokesperson said: "Boehringer Ingelheim is committed to expanding access to high-quality parasite prevention for dogs, which is why we’re proud to introduce an effective new option.
"Frontpro chewable tablets provide effective protection from fleas and ticks, while complementing the regular care and advice pet owners receive from their veterinarians."
www.uk.frontline.com
whatstherisk.co.uk has been created for all practice staff and contains advice from parasitologists Ian Wright and Eric Morgan.
Topics include advice on practical risk assessments, how risk-based prescribing can work with health plans as well as how to get owners involved to make risk assessment and personalised prescribing quicker and simpler.
Boehringer says that all the materials and advice have been developed in line with RCVS Practice Standards and the BVA's guidance on the responsible use of parasiticides.1,2
Sharron Woods, NexGard brands Franchise Manager said: “With knowledge about parasitic risk low among dog owners, alongside increasing scrutiny on the potential overuse of parasiticides, we’re delighted to be at the forefront of supporting vets, pet owners and the wider industry in driving best-practice risk assessment and responsible parasite control."
Boehringer says Senvelgo controls blood sugar levels usually within a week1,2 without the risk of symptomatic hypoglycaemia and without the need for twice daily insulin injections.
Studies have shown that around 1 in 200 cats develop diabetes4,5 - somewhere around 55,000 in the UK - of which 20% are euthanased within a year: 10% because of owners not wanting to inject with insulin, and a further 10% because of lack of success or compliance with insulin.3
This new treatment, with its once-daily oral treatment regime and simple dosing according to bodyweight, could have a significant impact on those numbers.
On top of which, there's no need for glucose curves to determine dosage, it's easily stored and doesn't need refrigeration, and it creates less waste than insulin (1 reusable oral syringe vs 180 insulin syringes).
Samantha Taylor BVetMed(Hons) CertSAM DipECVIM-CA MANZCVS FRCVS said: "This is the development in diabetes management we have been waiting many years for; a practical oral therapy to treat this challenging disease.”
To support vet professionals with using Senvelgo, Boehringer has produced a toolkit that includes a veterinary management guide, CPD webinar, cat owner leaflet and homecare journal, along with websites for vets and cat owners.
www.senvelgo.co.uk
Although the disease is commonly diagnosed later in life, a 2022 study of 123 dogs found that 40% of those aged between one and four years old had radiographic osteoarthritis, of which about half had clinical signs and of those only 2 were being treated for pain1.
Another 2022 study found that 38% of dogs over the age of one had osteoarthritic pain, but only half of them were presented for lameness or stiffness2.
Geoffrey Guyot, Pain and Inflammation Franchise Lead at Boehringer Ingelheim Animal Health, said: “Clinical signs of early osteoarthritis can be subtle.
"Some young dogs may present with overt lameness, but many compensate for years and manage to continue to perform their daily activities.
"Common compensations include gait or posture changes to unload the painful joint, which often go unnoticed.”
Boehringer says the aim of its campaign is to shift the perception of osteoarthritis as an old dog disease, to one which could affect dogs of all ages.
Boehringer also wants the campaign to bridge the gap between vets and dog owners, making it easier for owners to spot the early signs and initiate conversations about the condition.
Geoffrey added: "We hope the Arthritis AWARE campaign will raise awareness of early OA among owners to create more opportunities for you to diagnose and treat dogs with arthritis and improve their outcome.
"We encourage vet practices to join us on the journey so we can help improve dogs’ wellbeing together.”
Vet practices can help spread the word by downloading the Arthritis AWARE campaign pack which includes a waiting room video, a poster, owner-facing leaflets, and social media assets.
www.metacam.co.uk/aware
The toolkit includes a 15-minute CPD webinar: ‘How to best use ProZinc to successfully manage diabetes in cats and dogs’, hosted by Dr Jamie Adams BVSc PhD MRCVS, Senior Brand Technical Advisor at Boehringer Ingelheim.
Vet nurses who watch the webinar can enter a competition for a coffee machine for their veterinary practice by answering three questions at the end.
The toolkit also has a diabetes management reference guide covering how to make a confident diagnosis and start treatment with ProZinc, how best to monitor and reassess the patient and how to adjust the dose for optimal control.
There are also glucose curve charts, pet owner guides, home care journals and a link to the ProZinc pet owner website, www.prozinc.co.uk, which contains information to help owners feel confident in managing their pet’s diabetes.
The webinar and toolkit are available from: www.boehringer-academy.co.uk.
The online risk checker, which is available at www.parassess.co.uk, asks pet owners a series of questions to assess their dog's risk from fleas, ticks, lungworm roundworm and tapeworm.
The test, which has been developed with parasitologists, takes a few minutes and appears to produce sensible results (not every test produces a "Danger, high risk, emergency, get to your vet NOW" result, as you might expect if this had been entirely produced bv the marketing department).
The subsequent report can then be shared with the vet to review it and make a treatment decision.
Being online, the test can be taken on a smartphone whilst in the practice waiting room, or on tablet or computer at home.
It might be worth sharing the test with your clients by email or social media, inviting them to book an appointment if their results suggest it is necessary.
To that end, Boehringer Ingelheim has produced a range of communication materials, such as waiting room displays and digital content for web, email, SMS, and social media.
For more information, contact your local Boehringer Ingelheim territory manager or phone 01344 746957 (UK) or 01 291 3985 (Ireland).
Frontline wormer for cats contains praziquantel and pyrantel embonate, and for dogs it also contains febantel.
According to the company, Frontline Wormer is effective agains all types of intestinal worms found in the UK: roundworms, tapeworms, hookworms and whipworms.
It is presented as a palatable tablet which can be given as a treat without food, or mixed with food.
The press release from the company says the new product "gives pet parents an easy way to worm their cats and dogs".
"Pet parents?"
Someone please pass me the sick bag.
If I get one more press release describing cat or dog owners as 'pet parents", so help me god I will turn up at the press office and chain myself - naked - to the photocopying machine in protest.
It's a ghastly, patronising, cloying way to refer to people who own an animal, besides which, if I really was the parent of a pet, I would expect to be serving time at His Majesty's pleasure.
Frontline Wormer is available in packs of two tablets for 3 pet sizes.
As an AVM-GSL-licensed product, it can be sold off the shelf.
Renutend contains primed mesenchymal stem cells (MSCs) which Boehringer says are specifically targeted to reduce scar tissue formation so horses can return to the intended level of performance, with a reduced risk of re-injury1.
According to the company, a single dose decreases scar tissue formation with consistent and proven results 2.
RenuTend is administered by intralesional injection and complements Boehringer Ingelheim’s other equine stem cell product Arti-Cell Forte, which is authorised to treat mild to moderate recurrent lameness associated with non-septic joint inflammation in horses.
RenuTend will be available in September this year.
In the meantime, Boehringer is encouraging veterinary surgeons to register their interest with their BIAH representative or call 01344746960 in order to get updates or product information as soon as it becomes available.
NexGard Combo is a systemic isoxazoline-based endectocide designed specifically for cats which contains esafoxolaner, eprinomectin and praziquantel.
The new product provides one month’s protection against fleas and five week's protection against the most common tick on cats, Ixodes ricinus. It also treats the roundworms, Toxocara cati and Toxascaris leonina, hookworms, tapeworms and ear mites, against the last of which Nexgard Combo provides 97.2 to 99.9% efficacy following one treatment1.
NexGard Combo can be used in kittens from eight weeks of age and 0.8 kg in weight, making it suitable for most kittens at first vaccination. It is available in two pack sizes: small, for kittens weighing 0.8 - 2.5kg and large, for adult cats weighing 2.5 - 7.5kg. For cats weighing 7.5kg or over, an appropriate combination of applicators should be used.
Jackie Sterratt, senior brand manager at Boehringer Ingelheim, said: “We’re excited to add to the successful NexGard range and to help vets treat more cats. We know only one in two cats is treated for fleas2 and cats are only wormed on average three times per year3 despite all cats being at risk of fleas and most cats requiring monthly roundworming treatment2, 3, so there is a big opportunity to increase treatment rates and compliance. As the only product on the market to treat fleas, ticks, ear mites, roundworms and tapeworms, NexGard Combo offers a simple solution for cats at risk of multiple parasites."
To support the launch Boehringer has produced a marketing package which includes a kitten support pack, client leaflets, dispensing envelope and parasite risk checker.
For further information, contact your local Boehringer Ingelheim territory manager or phone 01344 746957 (UK) or 01 291 3985 (Ireland).
The company points to research which found that 89% of the veterinary profession wants to play a more active role in the sustainability agenda1.
For that reason, Boehringer says it put sustainability at the heart of Aservo EquiHaler, which uses no propellant gasses and the container for which is made from up to 50% recycled materials.
Now Boehringer has launched the first recycling programme for a prescription medicine in the UK to support the responsible disposal of the Aservo EquiHaler.
To join the programme, you need to visit: https://equihaler.uk/recycling, set up a TerraCycle account and register your practice. Boehringer says it only takes 10 minutes.
Once signed-up, a Boehringer Ingelheim Territory Manager will arrange for a collection box to be delivered, along with supporting practice display posters. When the box is full, there is a free pick-up service.
Practices that sign-up for the programme before 31st July 2021 will be entered into a prize draw, with the chance to win a year’s supply of ethically-sourced chocolate for their practice.
Reference:
Sally Rose RVN from Abervet in Aberdeen (pictured right), Jo Fuller RVN from Castle Vets in Farnborough and Gwen Raeburn RVN from Priory Close Vets in Somerset chose subscriptions to an arts and crafts ‘Witch Box’, a Hoppily Craft Beer Club box and a Nectar and Bumble box of bee-themed lifestyle items.
The nurses won the subscriptions after watching a NexGard Spectra online educational competition run in conjunction with BVNA during the association’s This is Us 2020 celebration of veterinary nursing.
Sally said: "It was great to receive the news that I’d won the BVNA NexGard Spectra competition. I thought it would be a simple task of looking through a few choices of prizes, however I didn’t realise that there were so many! When I came to it, I picked The Witch Box arts and crafts box. Thank you NexGard Spectra for the fantastic prize!"
The company says the new product has been 10 years in development and uses 'Soft Mist' technology - developed originally for human use by its pharma business - to deliver medication deep into the horse's lungs.
The active ingredient in the Aservo EquiHaler is ciclesonide, a corticosteroid that is activated directly in the lung, reducing the lower airway inflammation associated with severe equine asthma and reducing the risks commonly associated with systemic corticosteroids.
The Aservo EquiHaler does not use a propellant, so it does not contribute to greenhouse gas emissions. Boehringer also highlights that it is made from up to 50% recycled materials. In April, the product was awarded a Red Dot Design Award.
Dr Marc Laemmer, Head of Equine in UK & Ireland said: "It's another industry first and is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation.
"We understand that a product launch in this challenging time for the veterinary profession may seem surprising, but we have had such strong demand from equine vets for the product that we have committed to making Aservo EquiHaler available. Out team of territory managers and vet advisers will conduct remote meetings with customers to make sure that they have the information and support they require."
The webinar will consider questions such as how practices can maintain turnover whilst sticking to the government and regulator guidelines, and how this can be done without compromising the customer experience.
Hosted by Past President of the British Veterinary Association Gudrun Ravetz, three additional veterinary business experts - Brian Faulkner, Alison Lambert and Alan Robinson - will come together to share their advice on how to minimise the impact that coronavirus has on the practice, the team and a practice’s clients.
Veterinary professionals can submit questions directly to the panel who will answer them during the live event.
To register for the webinar, visit the Boehringer www.boehringer-academy.co.uk.
At the heart of the campaign is a website - www.beatdogheartdisease.co.uk - where dog owners can learn more about mitral valve disease and dilated cardiomyopathy, find out which breeds are most at risk and read more about the diagnosis and management of canine heart disease.
Boehringer has also created a Facebook page - www.facebook.com/beatcanineheartdisease - offering regular updates on heart health and a platform for owners to share their stories. Owners can also use the ‘Love Your Dog’s Heart’ Facebook profile frame to help spread awareness of the disease.
The aim of the campaign is to get pet owners thinking about mitral valve disease and having it treated whilst it is still in the asymptomatic phase, in order to slow the disease progression and delay the onset of heart failure1.
Vetmedin practices can access additional ‘Love Your Dog’s Heart’ campaign materials via the Boehringer Ingelheim Resource Hub at boehringer-ingelheim-resourcehub.co.uk.
Reference
Metacam is the first NSAID to be licensed for use in guinea pigs, and with it come the first guidelines for appropriate pain relief in this species.
Molly Varga, BVetMed DZooMed MRCVS, RCVS Specialist in Zoo and Wildlife Medicine, said: "Guinea pigs have evolved to hide pain and once obvious signs are visible it often indicates that the animal is no longer coping and its welfare has potentially been compromised. Appropriate pain management in guinea pigs is therefore vital, particularly after soft tissue surgery and regardless of whether signs of pain are visible, to ensure an enhanced recovery and optimal welfare."
Boehringer says that although signs of pain can be difficult to identify in guinea pigs, there are a few which indicate that the patient needs assessment and treatment:
Grinding teeth (a slow steady grind of the molars, different from chattering)
Reluctant to move or walk
Shivers or quivers, can sometimes see rippling along the body
Sits hunched, with hair spiky
Whimpers
Loss of appetite
Breathing may be heavy and laboured
The company adds that as the only licensed NSAID for use in guinea pigs, Metacam 0.5 mg/ml oral suspension should be considered for use in all soft-tissue surgery cases in this species.
Alongside the launch of the new indication, Boehringer has produced:
An interactive online dosage calculator to help with quick dose calculations. The company says higher doses can be used based on clinical judgement, allowing for tailoring of doses to individual cases.
A dosing dish and syringe to help owners administer Metacam at home.
A series of expert short videos, supported and narrated by Zoo and Wildlife Medicine specialist Molly Varga. The video series includes a guide to recognising pain in guinea pigs, dosing regimes and an owner video for accurately administrating Metacam at home.
The dosage calculator and the expert videos are available at https://www.boehringer-academy.co.uk. The dosing dish and syringe can be ordered directly from your Boehringer Territory Manager.
Eurican Herpes is used to vaccinate pregnant bitches to prevent mortality, clinical signs and lesions in puppies from canine herpes virus infections acquired in the first few days of life, through passive immunity. It is the only canine herpes vaccine.
Humphrey Grimmett, Business Head for the pet prescription portfolio at Boehringer Ingelheim said: “We do understand how disruptive and frustrating it is when vaccines such as Eurican Herpes aren’t available to veterinary practices.
“We would like to reassure veterinary practices that we are doing everything we can behind the scenes to re-establish supply of Eurican Herpes, and we thank them for their support and patience.”
For further information, contact Boehringer’s Technical Services Team on 01344 746957 or email vetenquiries@boehringer-ingelheim.com.
Equitop GLME is a palatable, pearl formulation joint supplement developed to support the healthy function of cartilage, joint capsules, tendons and ligaments. It is derived from an active extract of New Zealand Green Lip Mussels - a natural source of glucosaminoglycans (GAGs), chondroitin and essential fatty acids – and is tested free of prohibited substances.
Boehringer says the nutrients in Equitop GLME help to lubricate joints, as well as supporting normal joint function, the stability and elasticity of ligaments and the shock-absorbing properties of cartilage.
Equitop GLME is fed once a day either separately or mixed with feed and one tub will typically last for 30 days and can be used in all horses and ponies.
Dr Amy Scott, brand manager for Equitop GLME at Boehringer Ingelheim, said: "By encompassing Equitop GLME into the Equitop portfolio and launching easy-to-read new packaging, we are enhancing our product offering to both veterinary practices and horse owners."
For more information, contact your Boehringer account manager.
The Care About Cushing’s website is designed to give horse owners the information they need to spot the signs of Cushing's, thereby prompting diagnosis by their veterinary surgeon.
The online resource includes monitoring tools, personalised alerts, owner guides and webinars. It also offers downloadable self-assessment checklists on Cushing’s disease and laminitis to take owners through the signs to look out for.
Owners whose horses have been diagnosed with Cushing’s are encouraged to sign up as a Care About Cushing’s member to keep up-to-date with the latest information about the disease and create a personal profile for their horse in order to monitor progress. One of the membership benefits is an 'ask the expert' section where members can ask questions about Cushing’s disease and laminitis.
The Care About Cushing’s resource supports Boehringer’s ‘Talk About Laminitis’ initiative to raise awareness of the signs of laminitis and its link with Cushing’s disease.
Talk About Laminitis now runs throughout the year and as part of the campaign the laboratory fees for the blood test which detects Cushing’s (the basal ACTH test) are free.
Liz Barrett, equine business head at Boehringer, said: "Our Talk About Laminitis disease awareness initiative has been hugely successful in highlighting the link between laminitis and Cushing’s disease and helping to diagnose Cushing’s. So much so that Cushing’s is now in the top five equine diseases recorded in the UK1."
For further information on Talk About Laminitis or Care About Cushing’s, visit www.talkaboutlaminitis.co.uk, www.careaboutcushings.co.uk or contact your local Boehringer territory manager.
The research on which the new indication is based is described by Boehringer as the largest and most cutting-edge study in veterinary cardiology.
The EPIC study (Effect of Pimobendan in Dogs with asymptomatic MVD and Cardiomegaly)1 demonstrated that Vetmedin delayed the onset of heart failure for dogs with asymptomatic MVD, providing on average 15 months additional symptom-free time, as well as extending overall survival.
Indeed, Boehringer says the worldwide study was so conclusive - involving 360 dogs, in 36 centres, in 11 countries across four continents - that it was terminated early as it was deemed unethical to withhold Vetmedin from dogs in the placebo group.
Panny Morgan, Vetmedin brand manager at Boehringer Ingelheim, said: "Vetmedin delays the onset of heart failure in dogs with asymptomatic MVD and cardiomegaly, providing 15 months extra symptom-free time; that’s almost 10% of a dog’s lifetime.
"Prescribing Vetmedin to dogs with an MVD murmur and enlarged heart will not only extend a dog’s lifespan, but it will also have a major impact on their quality of life."
For further information on Vetmedin, contact your Boehringer Ingelheim territory manager or visit www.vetmedin.co.uk.
The recommendation follows the analysis of data collected as part of the company's Talk About Laminitis disease awareness initiative, which has seen more than 47,000 horses tested for PPID since it was launched in 20121.
The data revealed that, regardless of presenting clinical signs, a horse aged 15-20 is three times more likely to have PPID compared to a horse under 10, and this risk increases with age. For example, a horse of 20-25 is six times more likely to have PPID compared to a horse under 10 and a horse that is 25-30 is 10 times more likely to have PPID.
Boehringer says that despite the high prevalence of PPID in the older horse population, the clinical signs of the disease are insidious in onset and owners may simply associate them with the ageing process.
One study demonstrated that in a single population of horses over the age of 15 only 1.6% of owners reported signs of PPID2. However, when the same group of horses were examined by a veterinary surgeon, 21% were found to have signs of the disease.
Dr Jo Ireland, veterinary surgeon at the University of Liverpool, said: "It is often difficult for owners to spot the signs of PPID as they frequently associate them with the ageing process. However, PPID is now the fifth most commonly diagnosed disease in horses in the UK3.
"We are therefore encouraging veterinary surgeons to routinely test horses over 15 years of age or those that are displaying signs of PPID with an ACTH test."
The 'Talk About Laminitis' disease awareness initiative runs from June until the end of October and aims to raise awareness of the underlying hormonal causes of laminitis – PPID and Equine Metabolic Syndrome (EMS). As part of the scheme, the laboratory fees for the blood test which detects PPID (the basal ACTH test) are free.
Redwings’ head of veterinary and care, senior veterinary surgeon Nicky Jarvis, said: "Any initiative that decreases the incidence of laminitis developing in an older equine is invaluable. Laminitis is an extremely distressing condition for both the horse and the owner and the long-term consequences can be devastating. Knowing the underlying cause is a huge help in tackling the disease and we would encourage anyone to take advantage of this offer and get their veteran checked out."
For further information about 'Talk About Laminitis', visit www.talkaboutlaminitis.co.uk or contact your local Boehringer Ingelheim account manager.
Brand Manager Dr Amy Scott said: "Because pain is often very difficult for owners to spot, the website highlights some of the common signs that indicate their cat or dog is suffering.
"We have also included a range of additional measures that owners can take to improve the quality of life and maintain the joint health of their pet once Metacam has been prescribed. These include weight management, regular and gentle exercise and alternative therapies such as hydrotherapy or the use of joint supplements such as Seraquin."
The website highlights common painful conditions such as arthritis, as well as more acute scenarios such as post injury or surgery. It also describes the changes in behaviour owners should be aware of that could indicate their pet is in pain, for example reluctance to exercise, change in appetite, displays of aggression or depression.
Amy added: "The correct use of NSAIDs is also an important consideration for effective pain management. To help with this, the website contains a section on Metacam administration for owners, featuring a short video on accurate dosing and treatment."
The Boehringer Academy (www.boehringer-academy.co.uk) contains hundreds of hours of CPD material on equine, companion and production animals. It comprises a mixture of webinars, podcasts, short videos and downloadable documents, which can be viewed at any time. The site keeps a CPD log for each user and provides downloadable certificates.
Boehringer’s Small Animal Marketing Team Leader, Jemima Mead said: "We already have just over 15,000 vets and nurses in the UK and Ireland currently registered with the Academy.
"New and existing members are eligible to receive the Boehringer Academy colouring book. They simply have to visit www.boehringer-academy.co.uk and complete their profile. In addition, everyone completing their profile will be entered into a draw to win an iPad Pro and Apple Pencil."